Literature DB >> 20410770

Evaluation of the protein C global assay during normal pregnancy and after assisted reproduction.

Johnny S Younis1, Mervatte Shukha, Moshe Ben-Ami, Ido Izhaki, Zeev Blumenfeld, Benjamin Brenner, Galit Sarig.   

Abstract

OBJECTIVE: To prospectively compare the Protein C Global assay results in a cohort of infertile women who conceived after assisted reproductive technology (ART) with results from women who conceived spontaneously.
METHODS: Sixty-four infertile women who conceived after ART and 47 fertile women who conceived spontaneously were prospectively evaluated. All women in the study and control groups had singleton pregnancies. The Protein C Global assay was performed in the two groups on four occasions: during the first, second, and third trimesters, as well as 6 weeks or later after delivery (baseline).
RESULTS: Protein C Global assay results declined gradually during pregnancy in both groups. However, basal as well as first- and second-trimester Protein C Global assay results were significantly lower in the infertile group compared with the fertile group, corresponding to 0.89+/-0.22 and 1.06+/-0.33 (P=.025), 0.79+/-0.15 and 0.87+/-0.19 (P=.036), and 0.73+/-0.10 0.79+/-0.13 (P=.012), respectively.
CONCLUSION: These findings support the notion that infertile women conceiving singleton pregnancies after ART are a priori at an increased hypercoagulation state. Protein C Global assay levels decline gradually during pregnancy in women who conceived naturally, as well as in infertile women who conceived after ART treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20410770     DOI: 10.1097/AOG.0b013e3181db67f3

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  1 in total

1.  Reduced protein C Global assay level in infertile women prior to IVF-ET treatment.

Authors:  Johnny S Younis; Moshe Ben-Ami; Ido Izhaki; Benjamin Brenner; Galit Sarig
Journal:  J Assist Reprod Genet       Date:  2013-11-06       Impact factor: 3.412

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.